|
Video: What is a Stock Split?
|
|
Enveric Biosciences is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Co.'s pipeline of product candidates and ongoing development programs include: EV104 (Cannabidiol and Celecoxib Conjugate), which is used as the targeted indication of Osteoarthritis; EVM-201, which is used as the targeted indication of anxiety; EVM-301, which is used as the targeted indications of mental health indication; Cannabinoid-Infused Topical Product, which is used as the targeted indication of oncology-related skincare conditions; and Cannabinoid and COX-2 inhibitor Conjugation. According to our ENVB split history records, Enveric Biosciences has had 1 split. | |
|
Enveric Biosciences (ENVB) has 1 split in our ENVB split history database. The split for ENVB took place on July 15, 2022. This was a 1 for 50 reverse split, meaning for each 50 shares of ENVB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 20 share position following the split.
When a company such as Enveric Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ENVB split history from start to finish, an original position size of 1000 shares would have turned into 20 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Enveric Biosciences shares, starting with a $10,000 purchase of ENVB, presented on a split-history-adjusted basis factoring in the complete ENVB split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/05/2015 |
|
End date: |
04/22/2024 |
|
Start price/share: |
$2.50 |
|
End price/share: |
$0.86 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-65.56% |
|
Average Annual Total Return: |
-11.20% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3,444.53 |
|
Years: |
8.97 |
|
|
|
Date |
Ratio |
07/15/2022 | 1 for 50 |
|
|